Lassa Fever - Pipeline Insight, 2025

This “Lassa Fever - Pipeline Insight, 2025” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Lassa Fever pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Lassa Fever: Understanding

Lassa Fever: Overview

Lassa Fever is an acute viral hemorrhagic illness caused by the Lassa virus, which belongs to the Arenaviridae family. The disease is endemic in West African countries, including Nigeria, Sierra Leone, Liberia, and Guinea. Humans typically contract the virus through exposure to food or household items contaminated with urine or feces of infected Mastomys rats, the primary reservoir of the Lassa virus. Person-to-person transmission can also occur through direct contact with the blood, urine, feces, or other bodily secretions of an infected individual, posing significant risks to healthcare workers and those in close contact with infected patients.

The incubation period of Lassa Fever ranges from 6 to 21 days, and its clinical presentation can vary from mild to severe. Early symptoms often include fever, general weakness, and malaise, which can progress to more severe symptoms such as hemorrhaging, respiratory distress, repeated vomiting, facial swelling, pain in the chest, back, and abdomen, and shock. Neurological problems, including hearing loss, tremors, and encephalitis, may also occur in severe cases. The case-fatality rate is approximately 1% overall but can reach 15% among patients hospitalized with severe cases of Lassa Fever. Early supportive care with rehydration and symptomatic treatment improves survival, while the antiviral drug ribavirin has shown effectiveness if administered early in the course of the illness.

Preventing Lassa Fever primarily involves reducing contact with the Mastomys rodent population and implementing effective infection control practices. This includes storing food in rodent-proof containers, maintaining clean households, and using traps to reduce rodent populations. In healthcare settings, strict barrier nursing techniques, such as using protective clothing and proper disposal of medical waste, are crucial to prevent nosocomial infections.

'Lassa Fever- Pipeline Insight, 2025' report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Lassa Fever pipeline landscape is provided which includes the disease overview and Lassa Fever treatment guidelines. The assessment part of the report embraces, in depth Lassa Fever commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Lassa Fever collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Lassa Fever R&D. The therapies under development are focused on novel approaches to treat/improve Lassa Fever.

Lassa Fever Emerging Drugs Chapters

This segment of the Lassa Fever report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Lassa Fever Emerging Drugs

ARN-75039: Arisan Therapeutics

ARN-75039 is a broad-spectrum arenavirus entry inhibitor being developed by Arisan Therapeutics for the treatment of Lassa fever. ARN-75039 has shown efficacy in treating Lassa fever in guinea pigs. In a study, the compound was administered orally at 60 mg/kg once daily for 14 days starting 2, 4, or 6 days post-infection. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Lassa Fever.

Lassa Fever: Therapeutic Assessment

This segment of the report provides insights about the different Lassa Fever drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Lassa Fever

• There are approx. 3+ key companies which are developing the therapies for Lassa Fever. The companies which have their Lassa Fever drug candidates in the most advanced stage, i.e. Phase I include, Arisan Therapeutics.

Phases

The report covers around 3+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Lassa Fever pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Lassa Fever: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Lassa Fever therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Lassa Fever drugs.

Lassa Fever Report Insights

• Lassa Fever Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Lassa Fever Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Lassa Fever drugs?
• How many Lassa Fever drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Lassa Fever?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Lassa Fever therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Lassa Fever and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Arisan Therapeutics
• Imunon

Key Products

• ARN-75039
• IMNN-102

This product will be delivered within 2 business days.